Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1998-08-17
2000-10-03
Lankford, Jr., Leon B.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
424464, 514893, 514894, A61K 3578, A61K 920
Patent
active
061269425
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to a new medicinal compositions and methods of treating hepatic disorders.
BACKGROUND ART
Hepatic disorders, in particular those caused by viral infections, are a major health problem and the successful treatment of hepatic diseases poses a great challenge to the medical profession. With respect to hepatic diseases caused by viral infection, currently patients in advanced stages of the infection cycle (chronic hepatitis) with, for example, hepatitis C virus are treated with Interferon ("IFN") with only about 25% success rate. IFN is not readily available to patients and a six-month course of IFN therapy costs about $3000. It also gives rise to several side-effects such as severe flu symptoms, lethargy, hair loss and undesirable tastes in the mouth. IFN acts against the virus via the immune system and does not reverse any physiological abnormalities or damage caused by the infection eg. hepatic cirrhosis, diminished spleen function, etc. Furthermore, as there is a number of hepatic disorders which are not caused by viral infection, the administration of INF to patients with non-viral hepatic disorders would be ineffective.
It is an object of the present invention to provide an effective method of and medication for, treatment of both viral and non-viral hepatic disorders which avoids or at least ameliorates one or more of the disadvantages of current treatments.
SUMMARY OF THE INVENTION
According to a first aspect, the invention cat in a composition comprising the herbs Salvia miltiorrhiza and Polyporus umbellatus, or extracts thereof.
In a preferred embodiment the invention consists in a composition which further comprises at least one of the herbs Curcuma longa, Astragalus membranaceus, Loranthus parasiticus and Polygonum cuspidatum, or extracts thereof
In another preferred embodiment the invention consists in a composition which further comprises at least one of the herbs Poria cocos, Artemisia capillaris, Taraxacum mongolicum, Paeonia lactiflora, Panax pseudoginseng, Bupleurum falcatum, Cratagus pinnatifida, Glechoma longituba, Codonopsis pilosula, Lycium barbarum, Zizyphus jujuba, Gentiana manshurica and Glycyrrhiza uralensis, or extracts thereof.
According to a second aspect the invention consists in a composition comprising the herbs Salvia miltiorrhiza, Polyporus umbellatus, Poria cocos, Artemisia capillaris Taraxacum mongolicum, Paeonia lactiflora, Panax pseudoginseng, Bupleurum falcatum, Crataegus pinnatifida, Curcuma longa, Glechoma longituba, Astragalus membranaceus, Codonopsis pilosula, Loranthus parasiticus, Lycium barbarum, Polygonum cuspidatum, Zizyphus jujuba, Gentiana manshurica and Glycyrrhiza uralensis, or extracts thereof.
According to a third aspect, the invention consists in a method of treating hepatic disorders comprising the step of administering to a patient requiring such treatment any one of the compositions described above.
Preferably, the hepatic disorder treated is a non-viral hepatic disorder such as alcoholic hepatitis, cirrhosis or autoimmune liver disease.
More preferably the hepatic disorder treated is caused by a viral infection such as hepatitis virus A, B or C infection.
The treatment can be therapeutic or prophylactic, and may be administered orally or parenterally. The parenteral route could be topical, intravenous or subcutaneous. The treatment may be delivered in a single bolus dose, multiple doses or via a slow release device or a depot.
DESCRIPTION OF THE PREFERRED EMBODIMENT
In a preferred embodiment of the invention, the composition of the invention comprises Salvia miltiorrhiza and Polyporus umbellatus in the proportion of from 1:1 to 1:5 or 5:1. For example, these herbs may each comprise from 6 to 30% of the total weight of the herbal composition, the balance being made up for example by other herbs, preferably Curcuma longa (2-10%), Astragalus membranaceus (5-30%), Loranthus parasiticus (5-30%) and Polygonum cuspidatum (3-20%).
Although the administration of a composition containing only Salvia and Polyporus
REFERENCES:
patent: 4886666 (1989-12-01), Liu
Chung Kuo Chung Hsi I Chieh Ho Tsa Chi (China) Sep. 1993 13(9) Xiong L L "Therapeutic effects of combined therapy of Salvia Miltiorrhizae and Polyporus umbellatus polysaccharide in the treatment of chronic hepatitis B." p. 533-555, 516-517 Abstract.
Chung Hsi I Chieh Ho Tsa Chih (China) Apr. 1991 11(4) p225-6 (Abstract) Zhang, Y.H. et al "Effect of Polyporus umbellatus polysaccharide on function of macrophages in the peritoneal cavities of mice liver with lesions".
Chung Hsi I Chieh Ho Tsa Chi (China) Feb. 1991 11(2) p102-4 (Abstract) Qi, X.G., "Protective mechanism of Salvia miltiorrhiza and Paeonia lactiflora for experimental liver damage".
Chung Kuo Chung Yao Tsa Chih (China) Dec. 1992 17(12) p. 749-751 (Abstract) Yu, Z.P. et al. "Effects of Salvia miltiorrhiza Bunge on isolated perfused liver and protal vein of rats".
Journal of Ethnopharmacology 1987 19 p103-110, Ling-Ling Yang et al. "Antihepatoxic Actions of Formosan Plant Drugs".
Cancer Letters, 1986, 30, p. 143-151. Hajime Ohigashi et al. "Search for Possible Antitumour Promotors by Inhibition of the 12-0-Tetradecanoylphorbol-13-Acetate-Induced Epstein-Barr Virus Activation; Ursolic Acid and Oleanolic Acid from an Anti-inflammatory Chinese Medicinal Plant, Glechoma Hederaceae L.".
Planta Medica, 1994, vol. 60, p. 414-416 Yoshikazu Kondo et al. "Suppression of Chemically and Immunologically Induced Hepatic Injuries by Gentiopicroside In Mice".
Planta Medica, 1988, vol. 54, p. 413-414, Shean Farn Yeh et al. "Effects of Anthraquinones of Polygonum cuspidatum on HL-60 Cells".
A Textbook of Natural Medicine, 1993, vol. I, Joseph E. Pizzorno and Michael T. Murray, "Glycyrrhiza" V glycyr 3, Bastyr College Publications; Seattle, Washington.
Medicinal Plants in China, 1989, World Health Organization (WHO) Regional Publications Western Pacific Series No. 2, MANILA, pp. 30, 42, 48, 71, 84, 96, 97, 139, 150.
Healing with Chinese Herbs, 1990, Richard Hyatt, Healing Arts Press; Rochester, Vermont, pp. 113, 122, 133, 134, 139, 142.
Chung Hsi I Chieh Ho Tsa Chih (China), Aug. 1987, vol. 7(8), p. 483-4, Wang, S.L., et al, "Effects of Crataegus pinnatifidae, Astragalus membranaceus and Acanthopanax senticosus on cholesterol metabolism in the guinea pig". (Abstract).
Indian Journal of Exp Biol, Jul. 1989, vol. 27(7), p. 631-4, Dua et al., "Adaptogeaic activity of Indian Panax pseudoginseng".
Cathay Herbal Laboratories, Pty.
Lankford , Jr. Leon B.
Tate Christopher R.
LandOfFree
Herbal compositions for hepatic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herbal compositions for hepatic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herbal compositions for hepatic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-192378